Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes

doi:10.1158/1078-0432.CCR-10-1709

Clin Cancer Res. Author manuscript; available in PMC 2012 February 1.

Published in final edited form as:

Clin Cancer Res. 2011 February 1; 17(3): 437–446.

Published online 2010 November 22. doi: 10.1158/1078-0432.CCR-10-1709

PMCID: PMC3033467

NIHMSID: NIHMS249213

Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes

Julie M. Wu,¹ Andrew H. Beck,¹ Lisa L. Pate,¹ Daniela Witten,² Shirley X. Zhu,¹ Kelli D. Montgomery,¹ Kimberly H. Allison,³ Matt van de Rijn,¹ and Robert B. West^1,⁴

¹ Department of Pathology, Stanford University Medical Center, Stanford, CA

² Department of Statistics, Stanford University, Stanford, CA

³ Department of Pathology, University of Washington Medical Center, Seattle, WA

⁴ Pathology and Laboratory Service of Veterans Affairs Palo Alto Health Care System, Palo Alto, CA

Corresponding author: Robert B. West, M.D., Ph.D. Department of Pathology Stanford University Medical Center Room L235, 300 Pasteur Drive Stanford, CA 94305 Telephone: (650) 849-1294 FAX: (650) 725-7023 ; Email: rbwest/at/stanford.edu

The publisher's final edited version of this article is available free at Clin Cancer Res

See other articles in PMC that cite the published article.

Abstract

Purpose

We recently described two types of stromal response in breast cancer derived from gene expression studies of tenosynovial giant cell tumors and fibromatosis. The purpose of this study is to elucidate the basis of this stromal response – whether they are elicited by individual tumors or whether they represent an endogenous host reaction produced by the patient.

Experimental Design

Stromal signatures from patients with synchronous dual primaries were analyzed by immunohistochemistry on a tissue microarray (n=26 pairs) to evaluate the similarity of stromal responses in different tumors within the same patient. We also characterized the extent to which the stromal signatures were conserved between stromal response to injury compared to the stromal response to carcinoma using gene expression profiling and tissue microarray immunohistochemistry.

Results

The two stromal response signatures showed divergent associations in synchronous primaries: the DTF fibroblast response is more likely to be similar in a patient with multiple breast primaries (permutation analysis p=0.0027), while CSF1 macrophage response shows no significant concordance in separate tumors within a given patient. The DTF fibroblast signature showed more concordance across normal, cancer, and biopsy site samples from within a patient, than across normal, cancer, and biopsy site samples from a random group of patients, whereas the CSF1 macrophage response did not.

Conclusions

The results suggest that the DTF fibroblast response is host-specific, while the CSF1 response may be tumor-elicited. Our findings provide further insight into stromal response and may facilitate the development of therapeutic strategies to target particular stromal subtypes.

Keywords: breast cancer, tumor microenvironment, cancer stroma

Background

Although prognostication of malignant neoplasms has been classically focused on tumor histopathology, emerging studies have highlighted an interplay between tumor epithelium and stromal response, the results of which have significant implications for tumor progression and clinical outcome(1-15).. Olumi et al demonstrated that transplanted fibroblasts previously associated with prostatic carcinomas stimulated tumor progression compared to fibroblasts adjacent to normal prostatic epithelium(1). Ayala et al showed that specific stromal markers in prostatic carcinoma were significant predictors of recurrence-free survival(2). Furthermore, the amount of reactive stroma to prostate carcinomas was shown to be an independent predictor of cancer recurrence(3). In the area of breast carcinoma, Orimo et al showed that implanted carcinoma-associated fibroblasts promoted growth of carcinomatous epithelium more so than fibroblasts associated with normal epithelium(4).

Our previous studies of tenosynovial giant cell tumor and desmoid-type fibromatosis showed two distinct patterns of gene over-expression. Tenosynovial giant cell tumors and pigmented villonodular synovitis showed a macrophage-associated pattern of gene over-expression which we refer to as the “CSF1 response”. Desmoid-type fibromatosis and solitary fibrous tumors express a fibroblast-associated pattern of gene over-expression which we refer to as the “DTF response”. We subsequently applied these two patterns of gene expression to the study of stromal response in breast cancer. In doing so, we have characterized two sets of stromal response in breast cancer that are associated with tumor features and patient survival: the CSF1 macrophage stromal response signature was associated with higher tumor grade and decreased hormonal receptor expression(5), while the DTF fibroblast (fibromatosis-like) stromal signature was associated with lower grade tumors, estrogen receptor positivity and longer survival(6). In subsequent studies we showed that both CSF1 and DTF signatures could be identified in in situ lesions(16). Although the two stromal profiles have been characterized with respect to survival and tumor grade, it remains unclear whether these stromal responses are generated from a baseline host response to all malignant growth, or whether the tumor itself induces a specific set of stromal responses.

In the current study, we address the role of endogenous host response versus tumor-specific response by studying stromal signatures in patients with dual breast primaries. We then evaluated matched patient samples of normal stroma, biopsy site stroma, and stroma adjacent to carcinoma to distinguish tumor-specific response from generalized injury response.

Materials and Methods

Tumor samples for tissue microarrays

HIPAA compliant Stanford University Medical Center and University of Washington Medical Center (UWMC) institutional review board approval was obtained for this study. The UWMC pathology database was searched to identify patients with previously excised synchronous, independent primary breast cancers. Synchronous, independent primaries were defined as invasive carcinomas that either presented in separate breasts or as two clinically distinct carcinomas within the same breast. 26 patients with archival formalin fixed paraffin embedded tissue were identified with synchronous independent primary breast cancers for a total of 52 cases. (TA228, Table 1). In order to specifically study the stromal responses between normal, malignant, and biopsy site changes, a second tissue microarray (TMA 242) was constructed using the same material as that used in the breast scar gene expression profiling studies (see below). Areas representing a range of lesions were taken, including normal breast tissue (27 spots), granulomatous mastitis (2), previous biopsy sites (27), ductal carcinoma in-situ, DCIS (1), infiltrating ductal carcinoma, IDC (19), and infiltrating lobular carcinoma, ILC (2) for a total of 78 tissues.

Table 1

Dual Breast Primary Dataset

Evaluation of epithelial markers

Tissue sections were deparaffinized followed by blockade of endogeneous peroxidases and antigen retrieval using Antigen Unmasking Solution (Vector; USA). Estrogen receptor (ER) clone 1D5 using a dilution of 1:1000, following a 15 minute pre-treatment in citrate buffer, pH = 6.0; progesterone receptor (PR) (BioGenex, San Ramon, CA) clone PR88 using a dilution of 1:100 following an 18 minute pre-treatment in citrate buffer pH = 6.0; and Her-2/neu (Dako, Carpinteria, CA) using a dilution of 1:800, following a 15 minute pre-treatment in citrate buffer, pH = 6.0. The slides were then counterstained in hematoxylin, dehydrated, and mounted. Positive and negative controls were performed. HER2 was defined as positive if IHC was 3+ (strong circumferential membranous staining). It was considered negative in those tumors scoring 0-1+ (no to weak, non-circumferential staining). For those tumors with a 2+ score on IHC, gene amplification using FISH was used to determine HER2 status. HER2 was considered positive if the ratio of the copies of chromosome 17 to the number of HER2 gene copies was >2. Cellular proliferation was assessed by measurement of Ki-67 antigen by MIB-1 antibody (DAKO, Carpinteria, CA), scoring the percentage of positive cells. Ki-67 was stratified into 4 levels depending on percentage of nuclear labeling: score=0, <5% labeling; score=1, 5-10% labeling; score=2, 10-25% labeling, score=3, >25% labeling. Nottingham grade was scored using the modified Scarff-Bloom-Richardson system.

Evaluation of stromal markers

Tissue microarrays of synchronous breast cancers (TA228) and breast scar (TA242) were constructed and immunohistochemical (IHC) stains were performed. Serial sections of 4 μm were cut from the TMA blocks, de-paraffinized in xylene, and hydrated in a graded series of alcohol. The slides were pretreated with citrate buffer and a microwave step. The expression of five fibroblast response markers (DTF signature) was evaluated (cadherin 11, MMP 11, CSPG2, CD138, osteonectin). The expression of four macrophage response markers (CSF1 signature) was evaluated as well (cathepsin L, CD163, CD16, CD32). The primary antibodies used were osteonectin (Zymed, 1:1000 dilution, ENVISION Citrate), CSPG2 (Santa Cruz Biotechnology incorporated, 1:150 dilution, VECTOR citrate), cadherin 11 (Invitogen, Cat# 32-1700, 1:10 dilution, ENVISIOn citrate), SDC1 (CD138, Serotec, cat# MCA681H, 1:30 dilution, Ventana Benchmak Autostainer ventana mild CC1) and MMP11 (Calbiochem, Cat# IM86, 1:200 dilution, VECTOR citrate), Cathepsin L (CTSL1, MCA2374, mouse monoclonal; 1:25 dilution, AbD Serotec, ENVISION no preteatment ), CD163 (NCL-CD163, mouse monoclonal; Novocastra 1:100 dilution, Ventana Benchmak Autostainer ventana mild CC1), CD16 (FCGR3a; MCA1816, mouse monocloncal; AbD Serotec, 1:40 dilution, ENVISION citrate ), and CD32 (FCGR2a; AB45143, rabbit monoclonal; Abcam, 1:200 dilution, ENVISION Citrate). The immunohistochemical reactions were visualized using mouse and rabbit versions of the EnVision+ system (DAKO, Cambridgeshitre, United Kingdom) and Vector Vectastain Elite ABC mouse and rabbit systems (Vector Labs, Burlingame, CA, USA) using diaminobenzidine. CD163 and CD138 were done with Ventana Benchmark autostainer.

Paired primaries tissue microarray: IHC interpretation

The immunohistochemical studies were interpreted by histopathologic evaluation by the primary author (J.W.) with input from surgical pathologists (M.v.R. and R.B.W.) using previously published scoring criteria (5, 16).

Analysis of macrophage and fibroblast stromal response signature

The stromal signature score was determined by averaging the scores of the evaluable markers. Due to core loss from TMA sections, not all stains were evaluable for each tumor set. If fewer than four of the five markers were evaluable from the DTF series, or only three (or fewer) of the four markers were evaluable from the CSF1 series, the signature score was not included in the paired analysis. The stromal signature scores were calculated by averaging the scores for the evaluable markers. A total of seventeen cases of paired breast carcinomas were analyzed for concordance in stromal signatures. In order to assess for concordance in patient matched samples, a random permutation analysis was used to determine statistical significance. Cases were divided into random pairs and the average absolute difference in stromal signature score for each set of random pairs was computed. 200,000 iterations of this procedure were performed and p values were estimated by computing the proportion of iterations resulting in less average absolute difference than was observed in the actual paired data. The entire data set containing 52 cases (26 pairs) was used to evaluate associations of histologic subtype (ductal versus lobular) and tumor location (right versus left) between the two breast primaries. For the breast scar TMA (TA242), to analyze conservation of signatures within each patient compared to other patients, the mean standard deviation across normal, scar, and cancer observed in the patients is taken and then compared to the mean standard deviation following permutation of the samples. A total of 150 iterations were performed. The p value is computed as the proportion of permuted mean standard deviations that are less or equal to the true mean standard deviation.

Additionally, matched patient data were analyzed for intra-patient variations in stromal expression among normal, scar, and invasive carcinoma. To compare differences among normal, scar, and cancer stromal signatures from paired sets of samples, a Friedman test was performed. A total of 6 complete sets were analyzed for DTF and 8 complete sets were analyzed for CSF1. To examine differences between subcategories (i.e. normal stroma versus biopsy site, biopsy site versus carcinoma, normal stroma versus carcinoma) across all samples a Wilcoxon signed rank sum test was used. Comparisons were performed for DTF response profile between normal stroma versus biopsy site stroma (11 sets) and between normal stroma versus stroma surrounding carcinoma (6 sets). Similarly, comparisons were performed for CSF1 response profile between normal stroma and biopsy site stroma (12 sets) and between normal stroma and stroma surrounding carcinoma (8 sets). Lastly, Spearman correlation between DTF and CSF1 marker expression and days following biopsy was computed to assess for an association of marker expression with days following biopsy.

Breast scar gene expression array

In order to study the overall pattern of CSF1 and DTF marker expression in the context of breast scar tissue, expression profiling with gene microarrays were performed using material taken from archival material from a separate set of 16 patients seen at Stanford University Medical Center. Total RNA was isolated by using the RecoverAll Total Nucleic Acid isolation kit (Ambion Inc, Austin, TX. Catalog #1975) according to the manufacturer's protocol with some modifications. The paraffin-embedded tissue blocks were cut with a disposable microtome blade into 5-6 × 20 μm sections; and placed in RNAse-free Eppendorf tubes. The tissues were deparaffinized by 100% xylene and heat at 50C for 3 min and washed by 100% ETOH. After deparaffinization and centrifugation, the pellets were dried with Speed-vac for 5-10 min. Protease digestion was carried out by incubation at 50°C for 3 hours and 85C for 2 minutes with gentle agitation until complete digestion. DNase treatment and final purification were performed using a filter cartridge. The total RNA was eluted in 60 μL of RNase-free water, quantified, aliquoted, and stored at −80°C until use. Total RNA was amplified by using the Sense AMP RNA amplification kit (Genisphere Inc, Hatfield, PA). 250ng of total RNA was heated at 80°C for 10 minutes with dT and random primers. The Genisphere SenseAmp linear mRNA amplification method produces sense-strand amplified mRNA by incorporating a double stranded T7 promoter into the 3' end of the first strand cDNA, driving transcription of an amplified RNA with the same strandedness as mRNA. RNA amplification was carried out according to the manufacturers' instructions. The amplified Sense RNA (aRNA) was purified using the Rneasy minElute Cleanup Kit (Qiagen) and the eluate was collected in 15 μL RNase-free water. Amplified Sense RNA purity was determined by using a spectrophotometer to evaluate the A260/280 ratio. The fold-amplifications were evaluated by assuming that mRNA constitutes 1% to 5% of a total RNA population and only 20% of Sense RNA obtained from amplification was estimated to be true mRNA, whereas the rest could be amplified ribosomal RNA (http://www.genisphere.com/rna_amp_faqs.html and Sense AMP RNA amplification kit data sheet). The Human Exonic Evidence Based Oligonucleotide microarrays (HEEBO, Stanford) which contain 44,544 70-mer probes that were designed using a transcriptome-based annotation of exonic structure for genomic loci were used for expression profiling. The 5-10ug of amplified RNA was reverse-transcribed into cDNA using a mixture of oligo dT and random hexamer primers with incorporation of amino allyl-dUTP. Cy3 and Cy5 dyes were used for indirect labeling of the cDNA from amplified reference RNA (universal human reference RNA) and cDNA from amplified RNA of FFPE specimens. Microarray hybridization and washing was performed using standard procedures. Microarrays were scanned on a GenePix 4000 microarray scanner (Molecular Devices, Sunnyvale, CA).

Results

Stromal response in paired breast primaries

In prior studies we found that subsets of breast cancers are associated with discrete stromal gene signatures (5, 6, 13). To gain insight as to whether these signatures are initiated by the individual tumors or are specific to the host, we looked for intra-patient variation of both the DTF fibroblast and the CSF1 macrophage response signatures in 26 pairs of breast cancer samples from patients with dual breast primaries. The 52 breast cancer samples were assessed for these two signatures by immunohistochemistry using previously defined sets of 5 biomarkers for the DTF fibroblast signature (cadherin 11, MMP 11, CSPG2, CD138, and osteonectin) and 4 biomarkers for the CSF1 macrophage response signature (cathepsin L, CD163, CD16, CD32)(6, 13, 16).

The mean level of expression of DTF fibroblast response markers showed significantly less intra-patient discordance, i.e. more similarity, in matched primaries compared with the discordance observed in pairs of tumors from different patients (mean discordance = 0.78 in matched pairs vs. 1.21 in random pairs; p=0.007) [Table 2]. In contrast, the expression of CSF1 macrophage response markers did not show significantly more agreement in matched pairs from a single patient compared with un-matched pairs from separate patients (mean discordance = 0.71 in matched pairs vs. 0.80 in random pairs; p=0.22) [Table 2]. When examined individually, all DTF markers but only 2 of the 4 CSF1 markers show a trend for more concordance in matched primaries compared with random pairs (all p<0.10) [Table 2].

Table 2

Paired analysis

We also sought to assess the conservation of a set of additional biomarkers (ER, PR, Her2neu, Ki-67) and tumor characteristics (histologic subtype, tumor grade, size, laterality) in paired breast primaries. ER, PR and Her2neu could not be examined due to the lack of variation among the specimens. For the rest of the markers and tumor characteristics evaluated, only Ki-67 showed significant correlation between the two primaries (p=0.014) [Table 2]. There was no difference between the amount of stromal component in the breast primaries.

Stromal signature concordance within matched patient samples across normal, biopsy site and invasive carcinoma

To further characterize these stromal signatures in the overall setting of tissue injury response, we compared CSF1 macrophage and DTF fibroblast response patterns in the setting of normal breast, prior biopsy site, and invasive carcinoma by gene expression profiling. Cluster analysis for both the CSF1 macrophage and the DTF fibroblast core gene lists showed variation of signature profiles among patients in biopsy site stroma (Figure 1). This finding suggests that the CSF1 macrophage and DTF fibroblast response patterns show variable patterns of expression in biopsy site stroma, a process that we have previously characterized in breast cancer stroma(5, 6, 13).

Figure 1

Gene expression profiling for breast scars. Each column represents a scar taken from a different patient. Each row is a gene from the stromal reaction pattern gene list. Yellow represents relative high expression and blue represents relative low expression. (more ...)

To analyze these variations in detail, a tissue microarray of normal, biopsy site, and carcinoma-related stroma was constructed and analyzed with immunohistochemistry using the CSF1 macrophage and DTF fibroblast markers (Figure 2). The DTF fibroblast signature showed more concordance across normal, cancer, and biopsy site samples from within a patient, than across normal, cancer, and biopsy site samples from a random group of patients (p=0.04) [Table 3]. In contrast, the CSF1 macrophage signature did not show a significant concordance in lesions from a single patient compared to lesions from different patients (p=0.32). This result is consistent with the synchronous breast cancer portion of this study, where patients mounted consistent DTF fibroblast responses to their dual breast primaries.

Figure 2

Immunohistochemistry of selected DTF and CSF1 markers in breast scar tissue: A) CD16, B) MMP11, C) CathepsinL, D) Osteonectin.

Table 3

Normal vs Biopsy vs Carcinoma, TMA242 (Scar Tissue)

Stromal signature association with normal, biopsy site, and invasive carcinoma

The previous analysis determined the degree to which the stromal response was maintained within a patient across several tissue types (normal, cancer, biopsy site). We then determined the association of stromal response with sample type (normal, biopsy site, and carcinoma) using Friedman's test to detect non-parametric differences across the three sample types from matched patient samples. There was no significant difference across all three categories in CSF1 macrophage response marker expression (p=0.30), while DTF fibroblast response markers approached significance (p=0.083). We next performed a Wilcoxon sign-rank test to assess for an association between marker expression and tissue type across all patients. In contrast to Friedman's test, the Wilcoxon test was not limited to patients with matched data from multiple tissue types. In the DTF signature group, there was significantly increased expression in biopsy site change vs normal (p=0.0075), and a trend for increased expression in carcinoma versus normal (p=0.0892), with no significant difference between biopsy site change and carcinoma (p=0.1681). Therefore, the stromal expression of DTF markers varied most significantly when normal tissue is disrupted (normal versus biopsy site changes, normal versus carcinoma), and showed little difference between biopsy site changes and carcinoma. The CSF1 macrophage response showed a trend towards increased expression in biopsy site changes vs normal (p=0.0646), and no significant difference between biopsy site changes versus carcinoma (p=0.7974) or normal versus carcinoma (p=0.3829). These data suggest that the CSF1 response is not generated as a generalized response to tissue disruption.

Analysis of temporal relationship of stromal marker expression with days following biopsy

To assess temporal alterations in stromal marker expression, Spearman correlation was computed between DTF/CSF1 scores and number of days following initial core biopsy (Table 5). Of the individual markers, only MMP11 showed a marginally significant correlation of expression level with days following biopsy (Rho = 0.63; p = 0.03, uncorrected for multiple hypothesis testing). There was no significant association observed between time following biopsy and marker expression for any of the other individual markers, the CSF1 or DTF stromal signatures, or the markers averaged together (all p > 0.05).

Table 5

Biopsy Day Sequence, TMA242 (Scar Tissue)

Discussion

We have previously identified two stromal signatures that are present in a subset of breast cancers that correspond to clinical-pathologic features: the DTF fibroblast response signature, associated with lower tumor grade and increased survival(6, 13), and the CSF1 macrophage response signature, associated with decreased survival among low-grade tumors(5). We have found that these signatures are also present in pre-invasive cancer, i.e. ductal carcinoma in situ(16). A number of recent studies have identified stromal signatures that predict response to chemotherapy (15-17). We attempted to further understand the biology of stromal response by asking the following question: is the stromal response unique to the tumor, or is the stromal response an inherent reaction of the host to tissue alteration?

We approached this question by studying the variability in the stromal responses in clinically distinct tumors from the same patient. If the stromal response is dependent primarily on the tumor, we would not expect significant stromal response concordance between two separate tumors from the same patient. Therefore, in the first part of our study, we compared stromal responses to synchronous breast primaries in the same patient to determine whether stromal response to cancer is patient-dependent or tumor-provoked. If the stromal response is primarily dependent on the host, we would see a significant concordance in stromal responses between the two cancers from the same patient. In contrast, if the stromal response is largely dependent on the inciting tumor, we would not expect to see significant concordance in stromal responses from cancers derived from the same patient. In the second part of our study, we proceeded to ask whether the stromal response is a generalized response to tissue injury, or a specific response generated in reaction to the inciting tumor. We addressed this question by examining stromal signatures in normal breast, biopsy site changes, and carcinoma. If the stromal response is a tumor-specific reaction, we would anticipate significant differences in stromal signature response between biopsy site changes and carcinoma. If the stromal response is a more generalized response to tissue injury, we would anticipate significant differences in stromal signature response between normal tissue and biopsy site changes, but negligible differences between biopsy site changes and carcinoma. We then studied stromal response to biopsy site changes and carcinoma to delineate tumor-specific response from a more generalized tissue injury response. In doing so, we found that the two stromal signatures have divergent associations.

Our studies indicate that the DTF fibroblast response signature is significantly conserved in patients with paired breast primaries. In examining stroma taken from normal breast and biopsy site changes, we find that the response to biopsy site changes is similar to the response to carcinoma, and conclude that DTF fibroblast response is a more generalized response to tissue disruption and injury that appears to be specific to individual patients. This suggests that the DTF fibroblast response is a host-specific response and that the ability to generate this response varies between patients.

In contrast to the DTF fibroblast response, which showed significant concordance within a patient, the CSF1 macrophage response showed no significant concordance within patients with paired breast primaries. However, we cannot exclude that in a larger patient cohort, the CSF1 macrophage response signature may or may not show significant correlation as a couple of the markers within the signature show correlation within a patient. Because the response is increased in association with higher tumor grade, it may be that the CSF1 macrophage response is at least in part invoked by tumor.

These findings are in keeping with a separate study in our group on colon and breast cancer metastases, which demonstrated that DTF stromal expression is dependent on the tissue type (lymph node versus colon), while CSF1 stromal expression is conserved within the same tumor regardless of tissue background(17). This finding complements our conclusions from studying breast cancer, in that DTF appears to be not only patient specific, but tissue specific, while CSF1 response may be dependent on the individual tumor characteristics.

We have demonstrated two divergent stromal responses to breast cancer by studying marker expression in patients with synchronous breast primaries. A potential confounding factor would be if a patient developed two biologically similar tumors that would then induce the same stromal response. To evaluate whether epithelial markers were more conserved in paired primaries than would be expected by chance, we analyzed the paired breast primaries for conventional tumor biomarkers (ER, PR, Her2neu, and Ki-67) and tumor characteristics (histologic subtype, tumor grade, size, laterality). Of these features, the only one that attained statistical significance for concordance in paired primaries was Ki67 (p= 0.014), suggesting that proliferative index may be conserved in dual primaries. Due to the relatively small sample size and small amount of total variation in ER, PR and Her2neu across all the samples, our study was underpowered for identifying statistically significant conservation of these markers among paired primaries. We did not find any evidence of significant conservation of these makers, but we note that this hypothesis needs to be evaluated in a larger study with higher proportions of hormone receptor negative and Her2 positive patients. Taken together, our findings are consistent with evidence in the literature suggesting that dual breast primaries show distinct patterns of molecular alterations, based on molecular studies (18, 19), histologic subtype and hormonal receptor status (20-22), and by cytogenetics (23).

The interaction of cancer and stroma is reminiscent of the seed and soil theory proposed by Stephen Paget in 1889 to explain the preferential metastases of breast cancer to sites such as bone(24). In the case of cancer treatment, therapy has predominantly relied on attacking the “seed,” i.e. the epithelial component. Study of the “soil,” or the stroma, allows for understanding of the tumor microenvironment and opens up possibilities for a different direction of therapy. The study of the milieu in which breast cancer is situated is challenging, as the stromal response may be a product of tumor provocation as well as the patient's innate healing mechanism. In this paper, we have attempted a better understanding of this “soil,” in hopes that knowledge of the stromal response can in the future lead to novel treatments which create less fertile grounds for tumor growth.

Statement of Translational Relevance

This study examines the coincidence of specific stromal response signatures synchronous breast cancers. The findings provide insight towards understanding how these stromal responses arise in breast cancer and may lead to targeted therapies in the future.

Table 4

Intra-patient stromal response to biopsy and carcinoma, TMA242

Acknowledgments

Financial support:

Supported by the National Institutes of Health (CA129927) and the California Breast Cancer Research Program (15NB-0156).

Footnotes

Conflict of interest statement:

The authors and the study sponsors have no conflict of interest in this work.

References

1. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer research. 1999;59:5002–11. [PubMed]

2. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003;9:4792–801. [PubMed]

3. Yanagisawa N, Li R, Rowley D, et al. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Human pathology. 2007;38:1611–20. [PubMed]

4. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48. [PubMed]

5. Beck AH, Espinosa I, Edris B, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009;15:778–87. [PMC free article] [PubMed]

6. Beck AH, Espinosa I, Gilks CB, van de Rijn M, West RB. The fibromatosis signature defines a robust stromal response in breast carcinoma. Laboratory investigation; a journal of technical methods and pathology. 2008;88:591–601. [PubMed]

7. Bergamaschi A, Tagliabue E, Sorlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. The Journal of pathology. 2008;214:357–67. [PubMed]

8. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nature medicine. 2008;14:518–27. [PubMed]

9. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of experimental medicine. 2001;193:727–40. [PMC free article] [PubMed]

10. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11:R7. [PMC free article] [PubMed]

11. Nakopoulou L, Panayotopoulou EG, Giannopoulou I, et al. Stromelysin-3 protein expression in invasive breast cancer: relation to proliferation, cell survival and patients' outcome. Mod Pathol. 2002;15:1154–61. [PubMed]

12. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer research. 2006;66:5278–86. [PubMed]

13. West RB, Nuyten DS, Subramanian S, et al. Determination of stromal signatures in breast carcinoma. PLoS biology. 2005;3:e187. [PMC free article] [PubMed]

14. Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ. Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Human pathology [PubMed]

15. Cheng CW, Yu JC, Wang HW, et al. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clinica chimica acta; international journal of clinical chemistry. 411:234–41. [PubMed]

16. Sharma M, Beck AH, Webster JA, et al. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast cancer research and treatment. 2009 [PMC free article] [PubMed]

17. Webster JA, Beck AH, Sharma M, et al. Variations in stromal signatures in breast and colorectal cancer metastases. Journal of Pathology. 2010 [PMC free article] [PubMed]

18. Tse GM, Kung FY, Chan AB, Law BK, Chang AR, Lo KW. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. American journal of clinical pathology. 2003;120:168–74. [PubMed]

19. Saad RS, Denning KL, Finkelstein SD, et al. Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Mod Pathol. 2008;21:1200–7. [PubMed]

20. Sterns EE, Fletcher WA. Bilateral cancer of the breast: a review of clinical, histologic, and immunohistologic characteristics. Surgery. 1991;110:617–22. [PubMed]

21. Hungness ES, Safa M, Shaughnessy EA, et al. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. Surgery. 2000;128:702–7. [PubMed]

22. Dawson PJ, Maloney T, Gimotty P, Juneau P, Ownby H, Wolman SR. Bilateral breast cancer: one disease or two? Breast cancer research and treatment. 1991;19:233–44. [PubMed]

23. Pandis N, Teixeira MR, Gerdes AM, et al. Chromosome abnormalities in bilateral breast carcinomas. Cytogenetic evaluation of the clonal origin of multiple primary tumors. Cancer. 1995;76:250–8. [PubMed]

24. Paget S. The distribution of secondary growths in cancer of the breast. Cancer metastasis reviews. 1989;8:98–101. 1889. [PubMed]